InspireMD Promotes MGuard™ at the EuroPCR 2011 Exhibition and Conference in Paris This Week

PARIS, May 16, 2011 /PRNewswire/ -- InspireMD, Inc. (OTCBB: NSPR) ("Inspire" or the "Company"), the developer of the MGuard™ mesh protective stent system, will partake in the EuroPCR conference this week. MGuard, and the recently launched MGuard Prime, InspireMD's new Cobalt Chromium mesh protective stent system will be on display at booth #P14.  Both products feature InspireMD's MicroNet® Mesh Technology, a potentially superior solution for thrombus management in heart attack patients. MGuard Prime is CE Marked and indicated for Primary PCI for STEMI, Saphenous Vein Grafts and ACS with visible thrombus.

InspireMD's cocktail reception and scientific symposium will take place Wednesday, May 18th at 6:30 p.m. adjacent to the EuroPCR conference at the Concorde Lafayette Hotel, Paris, Grande Etoile D'Or Hall.  The symposium will be chaired by Dr. Martin Leon and the meeting faculty includes Drs. Alexandre Abizaid, Antonio Colombo, Dariusz Dudek, Eberhard Grube, Chaim Lotan, Sigmund Silber and more. The session, titled, "Thrombus Management in STEMI: MGuard and the MASTER Trial," will reveal recent clinical data of MGuard in STEMI patients as well as important insights into the MGuard MicroNet® Mesh Technology and presentations and discussion of recent challenging MGuard PPCI cases.  

Also on Wednesday, May 18, at 8 a.m., Dr. Anthopoulos will present "Single-centre experience using MGuard stent platform in primary PCI in STEMI" at the session of Primary PCI in STEMI patients: new techniques Session comprising selected EuroPCR 2011 abstract submissions in room 243.  

On Thursday, May 19th at 1 p.m., Dr. Esteves will present: "Comparative analysis of a distal protection system and the new stent M-Guard for the treatment of complex lesions in saphenous vein grafts" as part of the session: DES / protection devices in saphenous vein graft PCI in room 353 Technique.

Finally, don't miss the InspireMD Booth Party on Thursday May 19th at 5 p.m. InspireMD invites all EuroPCR visitors to come and join its celebration where we will draw a winner in our lottery for a new iPad and raise a toast for the recent MGuard clinical results and for the commencement of the MASTER randomized trial.  

About MGuard™ Coronary

MGuard™ presents a novel combination of a coronary stent merged with an embolic protection specifically designed for Acute MI patients. The embolic protection is comprised of an ultra-thin polymer mesh sleeve that wraps the stent. The MGuard™ coronary seeks to provide permanent embolic protection, without affecting deliverability. MGuard™ is CE Mark approved. Mesh-based protection is now recommended for use in the recent Guidelines of the Task force of Myocardial Revascularization of the European Society of Cardiology (ESC).

About InspireMD Ltd.

InspireMD is an innovative medical device company focusing on the development and commercialization of its proprietary stent system technology, MGuard™. InspireMD intends to pursue applications of this technology in coronary, carotid and peripheral artery procedures. InspireMD's common stock is listed on the OTC BB under the ticker symbol "NSPR".

Forward-looking Statements:

This press release contains "forward-looking statements." Such statements may be preceded by the words "intends," "may," "will," "plans," "expects," "anticipates," "projects," "predicts," "estimates," "aims," "believes," "hopes," "potential" or similar words. Forward-looking statements are not guarantees of future performance, are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company's control, and cannot be predicted or quantified and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties associated with (i) market acceptance of our existing and new products, (ii) negative clinical trial results or lengthy product delays in key markets, (iii) an inability to secure regulatory approvals for the sale of our products, (iv) intense competition in the medical device industry from much larger, multi-national companies, (v) product liability claims, (vi) our limited manufacturing capabilities and reliance on subcontractors for assistance, (vii) insufficient or inadequate reimbursement by governmental and other third party payers for our products, (viii) our efforts to successfully obtain and maintain intellectual property protection covering our products, which may not be successful, (ix) legislative or regulatory reform of the healthcare system in both the U.S. and foreign jurisdictions, (x) our reliance on single suppliers for certain product components, (xi) the fact that we will need to raise additional capital to meet our business requirements in the future and that such capital raising may be costly, dilutive or difficult to obtain and (xi) the fact that we conduct business in multiple foreign jurisdictions, exposing us to foreign currency exchange rate fluctuations, logistical and communications challenges, burdens and costs of compliance with foreign laws and political and economic instability in each jurisdiction. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's filings with the Securities and Exchange Commission, including the Company's Current Report on Form 8-K filed with the SEC on April 6, 2011. Investors and security holders are urged to read these documents free of charge on the SEC's web site at www.sec.gov. The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.

Company Contact:
www.inspire-md.com
Jonina Ohayon
Marketing Director
[email protected]
OTC BB: NSPR

Investor Contact:
Jeffrey Stanlis
Partner, Hayden IR
[email protected]
(602) 476-1821

SOURCE InspireMD